Main Article Content
Abstract
Le syndrome des antisynthétases (SAS) est une myopathie inflammatoire idiopathique d’expression clinique variable et hétérogène. L’atteinte pulmonaire est la plus fréquente des manifestations et constitue un facteur majeur de pronostic de la maladie. Les manifestations extra-pulmonaires sont multiples, peuvent concerner les articulaires, la musculature, la peau, le digestif et aussi rénale. Le SAS peut s’associer à d’autres connectivites telle la maladie de Goujerot-Jogreen ou survient aussi sur des terrains particuliers comme la drépanocytose. La présence d’anticorps ARNt synthétase associant une atteinte pulmonaire et extra-pulmonaire à type de myopathie, doit faire évoquer le diagnostic de SAS. La corticothérapie systémique est le chef de fil du traitement et le plus souvent en association aux immunosuppresseurs, voire d’emblée pour les cas d’atteinte pulmonaire sévère.
ABSTRACT
Antisynthetase syndrome (SAS) is an idiopathic inflammatory myopathy of variable and heterogeneous clinical expression. Pulmonary involvement is the most frequent manifestation and is a major prognostic factor for the disease. The extra-pulmonary manifestations are multiple and may involve the joints, muscles, skin, digestive system and also the kidneys. SAS can be associated with other connective tissue diseases such as syndrom Goujerot-Jogreen's disease or also occurs in specific areas such as sickle cell disease. The presence of tRNA synthetase antibodies associating pulmonary and extra-pulmonary damage with a type of myopathy should suggest the diagnosis of SAS. Systemic corticosteroid therapy is the mainstay of treatment and most often in association with immunosuppressants, or even immediately in cases of severe pulmonary disease.
Article Details
References
- Diagnostics difficiles en médecine interne. 4ème Edition Maloine. 2018 ; 2 : 618 (353)
- Brouwer R, Hengstman GJD, Egberts WV, et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001 ; 60 : 116 – 23.
- Antisynthetase syndrome. Derm Net NZ. Decembre 2014 http://Dermnetnz.org/immune/antisynthetase.html
- Antisynthetase syndrome. Orphanet.May 2014 ; http://www.orphanet/consor/cgibin/Disease-search.php?
- Frihka F, et al. Caracteristiques cliniques et immunologiques des patients avec des anticorps anti-Jo1 positif. Rev Med interne 2017 ; 38 :171 -2.
- Mirrakhimov AE. Antisynthetase syndrome : a review of etiopathogenesis, diagnosis and management. Curr Med Chem. 2015 ; 22 (16) : 1963 – 75.
- Marguerie C, Bunn CC, Beynon HL, et al. Poplymyositis, pulmonary fibrosis and autoantibodies to aminoacylètrna synthetase enzymes. Q J Med 1990 ; 77 : 1019 – 38.
- Lamini N’Soundhat Norbert Edgard, Ntsiba Honoré. Les Maladies Auto Immunes et de Système au Service de Rhumatologie du Centre Hospitalier Universitaire de Brazzaville. Health Sci. Dis: Vol 21 (4) April 2020
- Hervier B, Devilliers H, Stanciu R, et al. Hierarchical cluster and survival analysies of antisynthetase syndrome : phenotype and outcome are correlated with anti-trna synthetase antibody specificity. Autoimmun Rev 2012 ; 12 : 210 – 7.
- Bohan A, Peter JB. Polymyosistis and dermotomyosiits. N Engl J Med 1975 ; 292 : 344 – 7.
- Marie I, Josse S, Decaux O, et al. Comparison of longterm outcome between anti-Jo1- and anti-PL 7 / PL 12 positive patients with antisynthetase syndrome. Autoimmun Rev 2012 ; 11 : 739 – 45.
- Labirua-Iturburu A, Selva-O’Callaghan A, Vincze M, et al. Anti PL7 (anti-threonyl-trna synthetase) anti synthetase syndrome : clinical manifestations in a seris of patients from literature. Medecine 2012 ; 91 : 206 – 11.
- Marie I, Josse S, Hatron PY, et al. Interstitial lung disease in anti-Jo1 patients woth antisynthetase syndrome. Arthritis care Rev 2013 ; 65 : 800 – 8.
- Labirua A, Lundberg IE. Interstitial lung disease and idiopathic inflammatory myopathies : progress and pitfalls. Curr Opin Rheumtol 2010 ; 22 : 633 – 8
- S. Jouneau, B. Hervier, E. – M. Jutant, et al. Les manifestations pulmonaires du syndrome des antisynhtetases. Rev 2015 ; 32 : 618 – 28.
- Niza EL Bouardi, Amina Alaoui, Meriem Haloua, et al. Une pneumopathie interstitielle diffuse revélant un syndrome,des antisynthétases : à propos de 2 cas. Pan African Med. J. 2019 ; 32 : 40.
- Fujisawa T, Suda T, Nakamura Y, et al. Differences in slinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J. Rheumatol 2013 ; 40 : 1777 – 9.
- Tillie-Leblond I, Wisley M, Valeyre D, et al. Interstitial lung disesase and anti-Jo1 antibodies : difference between acute and gradual onset. Thorax 2008 ; 63 : 53 – 9.
- Hervier B, Benveniste O. phenotypes cliniques et pronostic du syndrome des antisynthétases. Rev Med interne 2014 ; 35 : 453 – 60.
- Hervier B, Meyer A, Dieval C, et al. Pulmonary hypertension in antisynthetase syndrome : prevalence, aetiology and survival. Eur Respir J. 2013 ; 42 : 1271 – 82.
- Chatterjee S, Farver C. severe pulmonary hypertension in anti-Jo1 syndrome. Arthritis Care Res 2010 ; 62 : 425 – 9.
- Schmidt WA, Wetzel W, Friedlander R, et al. Clinical and serological aspects of patients with anti-Jo1 antibodies an evolving apectrum of disease manifestations. Clin Rheumatol 2000 ; 19 : 371 – 7.
- Park CK, Kim TJ, Cho YN, et al. Development of antisynthetases syndrome in a patient with rheumatoid arthritis. Rheumatol int 2011 ; 31 : 529 – 32.
- Selva-O’Callaghan A, Labrador-Horrillo M, Solans-Laque R, et al. Myositis specific and myositis associated antibodies in a series of eighty-eight mediterranean patients with idiopathic inflmmatory myopathy. Arthritis Rheum 2006 ; 55 : 791 – 8.
- A. Kanfer, O. Kourilsky, M.-N. Peraldi, C. Combe. Néphrologie et troubles hydroélectrolytiques. 2014 ; 455 : 208 -9.
References
Diagnostics difficiles en médecine interne. 4ème Edition Maloine. 2018 ; 2 : 618 (353)
Brouwer R, Hengstman GJD, Egberts WV, et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001 ; 60 : 116 – 23.
Antisynthetase syndrome. Derm Net NZ. Decembre 2014 http://Dermnetnz.org/immune/antisynthetase.html
Antisynthetase syndrome. Orphanet.May 2014 ; http://www.orphanet/consor/cgibin/Disease-search.php?
Frihka F, et al. Caracteristiques cliniques et immunologiques des patients avec des anticorps anti-Jo1 positif. Rev Med interne 2017 ; 38 :171 -2.
Mirrakhimov AE. Antisynthetase syndrome : a review of etiopathogenesis, diagnosis and management. Curr Med Chem. 2015 ; 22 (16) : 1963 – 75.
Marguerie C, Bunn CC, Beynon HL, et al. Poplymyositis, pulmonary fibrosis and autoantibodies to aminoacylètrna synthetase enzymes. Q J Med 1990 ; 77 : 1019 – 38.
Lamini N’Soundhat Norbert Edgard, Ntsiba Honoré. Les Maladies Auto Immunes et de Système au Service de Rhumatologie du Centre Hospitalier Universitaire de Brazzaville. Health Sci. Dis: Vol 21 (4) April 2020
Hervier B, Devilliers H, Stanciu R, et al. Hierarchical cluster and survival analysies of antisynthetase syndrome : phenotype and outcome are correlated with anti-trna synthetase antibody specificity. Autoimmun Rev 2012 ; 12 : 210 – 7.
Bohan A, Peter JB. Polymyosistis and dermotomyosiits. N Engl J Med 1975 ; 292 : 344 – 7.
Marie I, Josse S, Decaux O, et al. Comparison of longterm outcome between anti-Jo1- and anti-PL 7 / PL 12 positive patients with antisynthetase syndrome. Autoimmun Rev 2012 ; 11 : 739 – 45.
Labirua-Iturburu A, Selva-O’Callaghan A, Vincze M, et al. Anti PL7 (anti-threonyl-trna synthetase) anti synthetase syndrome : clinical manifestations in a seris of patients from literature. Medecine 2012 ; 91 : 206 – 11.
Marie I, Josse S, Hatron PY, et al. Interstitial lung disease in anti-Jo1 patients woth antisynthetase syndrome. Arthritis care Rev 2013 ; 65 : 800 – 8.
Labirua A, Lundberg IE. Interstitial lung disease and idiopathic inflammatory myopathies : progress and pitfalls. Curr Opin Rheumtol 2010 ; 22 : 633 – 8
S. Jouneau, B. Hervier, E. – M. Jutant, et al. Les manifestations pulmonaires du syndrome des antisynhtetases. Rev 2015 ; 32 : 618 – 28.
Niza EL Bouardi, Amina Alaoui, Meriem Haloua, et al. Une pneumopathie interstitielle diffuse revélant un syndrome,des antisynthétases : à propos de 2 cas. Pan African Med. J. 2019 ; 32 : 40.
Fujisawa T, Suda T, Nakamura Y, et al. Differences in slinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J. Rheumatol 2013 ; 40 : 1777 – 9.
Tillie-Leblond I, Wisley M, Valeyre D, et al. Interstitial lung disesase and anti-Jo1 antibodies : difference between acute and gradual onset. Thorax 2008 ; 63 : 53 – 9.
Hervier B, Benveniste O. phenotypes cliniques et pronostic du syndrome des antisynthétases. Rev Med interne 2014 ; 35 : 453 – 60.
Hervier B, Meyer A, Dieval C, et al. Pulmonary hypertension in antisynthetase syndrome : prevalence, aetiology and survival. Eur Respir J. 2013 ; 42 : 1271 – 82.
Chatterjee S, Farver C. severe pulmonary hypertension in anti-Jo1 syndrome. Arthritis Care Res 2010 ; 62 : 425 – 9.
Schmidt WA, Wetzel W, Friedlander R, et al. Clinical and serological aspects of patients with anti-Jo1 antibodies an evolving apectrum of disease manifestations. Clin Rheumatol 2000 ; 19 : 371 – 7.
Park CK, Kim TJ, Cho YN, et al. Development of antisynthetases syndrome in a patient with rheumatoid arthritis. Rheumatol int 2011 ; 31 : 529 – 32.
Selva-O’Callaghan A, Labrador-Horrillo M, Solans-Laque R, et al. Myositis specific and myositis associated antibodies in a series of eighty-eight mediterranean patients with idiopathic inflmmatory myopathy. Arthritis Rheum 2006 ; 55 : 791 – 8.
A. Kanfer, O. Kourilsky, M.-N. Peraldi, C. Combe. Néphrologie et troubles hydroélectrolytiques. 2014 ; 455 : 208 -9.